Pallas Capital Advisors LLC Takes $1.20 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Pallas Capital Advisors acquired 1,920 Regeneron shares worth approximately $1.20 million in the second quarter, while institutional investors collectively own 83.31% of the stock.
• Regeneron reported quarterly EPS of $14.29, beating estimates by $4.13, on revenue of $4.29 billion—up 16.7% year over year. The company also declared a $0.94 quarterly dividend, representing a 0.5% yield.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an $801.70 target price, although litigation related to alleged disclosures surrounding the failed fianlimab-Libtayo trial presents legal and commercial risks.

Pallas Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,920 shares of the biopharmaceutical company's stock, valued at approximately $1,197,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $11,358,000. Lockheed Martin Investment Management Co. acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $2,702,000. National Pension Service grew its holdings in shares of Regeneron Pharmaceuticals by 29.8% in the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company's stock worth $278,636,000 after purchasing an additional 82,853 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $10,472,000. Finally, Contravisory Investment Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $6,327,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN opened at $810.24 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The stock has a market capitalization of $83.42 billion, a P/E ratio of 20.03, a price-to-earnings-growth ratio of 1.37 and a beta of 0.21. The company's 50 day simple moving average is $683.57 and its 200-day simple moving average is $714.66. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals's revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $12.81 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on REGN shares. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating on the stock in a research report on Thursday, July 9th. Truist Financial raised their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a report on Friday, July 31st. Barclays cut their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating for the company in a research report on Thursday, April 30th. Finally, HSBC decreased their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating on the stock in a report on Monday, July 6th. Sixteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $801.70.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Leerink raises price target: Leerink Partners increased its REGN price target from $641 to $824, implying modest additional upside. However, the firm retained a “market perform” rating, suggesting limited conviction in a stronger near-term advance. Benzinga analyst price target report
• Neutral Sentiment: Class-action deadline approaches: Several law firms, including Pomerantz, Hagens Berman, Faruqi & Faruqi, and The Schall Law Firm, reminded investors of a September 14, 2026 deadline to seek lead-plaintiff status in a securities lawsuit. These announcements largely repeat previously reported information and do not represent a new financial or regulatory finding. Pomerantz investor alert
• Negative Sentiment: Litigation highlights clinical-trial concerns: The lawsuits allege that Regeneron made misleading statements about clinical differentiation and slowing event accrual in the Phase 3 fianlimab-Libtayo study, potentially understating the risk that the trial would miss its primary endpoint. The trial failure reportedly erased roughly $11 billion in market value and could create ongoing legal costs, reputational risk, and uncertainty around the program’s commercial prospects. The allegations have not been proven. Hagens Berman Regeneron class-action notice

Insider Activity

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $482,400. The trade was a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock valued at $1,090,030 over the last 90 days. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source